NVO - Novo Nordisk A/S

NYSE - Nasdaq Real Time Price. Currency in USD
43.285
+0.985 (+2.33%)
As of 2:18PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close42.300
Open42.890
Bid43.220 x 800
Ask43.230 x 800
Day's Range42.765 - 43.310
52 Week Range41.230 - 58.370
Volume1,320,565
Avg. Volume1,542,258
Market Cap105.499B
Beta (3Y Monthly)0.85
PE Ratio (TTM)17.34
EPS (TTM)2.496
Earnings DateN/A
Forward Dividend & Yield1.27 (2.98%)
Ex-Dividend Date2018-08-17
1y Target Est47.20
Trade prices are not sourced from all markets
  • 6 Companies Growing Their Book Value
    GuruFocus.com22 hours ago

    6 Companies Growing Their Book Value

    Brookfield Asset Management tops the list

  • Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
    Reutersyesterday

    Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

    Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.

  • PFE or NVO: Which Is the Better Value Stock Right Now?
    Zacksyesterday

    PFE or NVO: Which Is the Better Value Stock Right Now?

    PFE vs. NVO: Which Stock Is the Better Value Option?

  • Reutersyesterday

    Novo Nordisk could close biopharma acquisition this year - CEO

    COPENHAGEN (Reuters) - Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday. "It is not always easy ...

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist5 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • How Novartis’s Businesses Have Been Performing
    Market Realist6 days ago

    How Novartis’s Businesses Have Been Performing

    Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business

  • Benzinga8 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

    As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist11 days ago

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • Lilly's Novel Diabetes Candidate Shows Promise in Phase II
    Zacks11 days ago

    Lilly's Novel Diabetes Candidate Shows Promise in Phase II

    Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.

  • 7 Healthcare Stocks to Buy Right Now
    InvestorPlace12 days ago

    7 Healthcare Stocks to Buy Right Now

    How will the Donald Trump administration’s continued efforts to overhaul the tax code affect healthcare companies in coming years? For many investors, the grave uncertainty about the political playing field has led them to stay away. On top of that, the seven healthcare stocks we talk about in this article offer a wide range of products and services within the industry, and several are in niches less vulnerable to regulatory shake-ups.

  • Lilly's diabetes drug data impresses, hurts rival Novo's shares
    Reuters12 days ago

    Lilly's diabetes drug data impresses, hurts rival Novo's shares

    The novel drug targets two key gut hormones at the same time, and could pose a threat to currently available single-hormone drugs, which form a large and growing part of Novo's business. Lilly's treatment reduced blood sugar levels in type 2 diabetes patients by up to 2.4 percent and produced an average weight reduction of up to 12.7 percent in a mid-stage study by targeting the GLP-1 and GIP hormones.

  • Bloomberg12 days ago

    Diabetes Drug's Results Push Lilly to Look at Obesity Too

    The drug showed an average reduction of as much as 12.7 percent in weight and up to 2.4 percent in blood sugar in the midstage research, Lilly said in a statement Thursday. Lilly rose 4.2 percent to $113.10 in New York before U.S. exchanges opened. The company now plans “very broad” late-stage studies in diabetes that will likely begin by early 2019 and look at different drug combinations, said Brad Woodward, senior medical director at Lilly’s diabetes unit.

  • How GlaxoSmithKline’s Vaccines Business Has Performed Recently
    Market Realist14 days ago

    How GlaxoSmithKline’s Vaccines Business Has Performed Recently

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.

  • How GlaxoSmithKline’s Segments Performed
    Market Realist15 days ago

    How GlaxoSmithKline’s Segments Performed

    GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.

  • Sanofi Stock Up 2.8% in September: What Lies Ahead?
    Market Realist18 days ago

    Sanofi Stock Up 2.8% in September: What Lies Ahead?

    On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion. The stock rose 1.2% that day from its previous day’s closing price. It traded at its 52-week high of $50.64 on October 6, 2017. It registered its 52-week low of $37.43 on May 9, 2018. Currently, SNY stock is trading above its 50-day moving average of $42.89 as well as its 200-day moving average of $40.89.

  • A Look at Eli Lilly’s Revenue Growth Rate
    Market Realist18 days ago

    A Look at Eli Lilly’s Revenue Growth Rate

    Eli Lilly and Company (LLY) reported revenue of ~$6.4 billion in the second quarter, surpassing Wall Street analysts’ estimates for revenue in the period.

  • Sanofi Stock: How Much Upside Potential Does Wall Street See?
    Market Realist18 days ago

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    Sanofi (SNY) is a global biopharmaceutical company, headquartered in France, with a market capitalization of $110.7 billion. It offers an expansive product portfolio that offers solutions across disease segments, including multiple sclerosis, immunology, neurology, oncology, cardiovascular diseases, diabetes, vaccines, infectious diseases, and rare disease disorders.

  • Novo Nordisk to cut 250 jobs in the United States
    Reuters18 days ago

    Novo Nordisk to cut 250 jobs in the United States

    Denmark's Novo Nordisk (NOVOB.CO) will cut around 250 jobs in the United States, a spokesman told Reuters on Friday, adding the drugmaker would also hire an as-yet undetermined number of staff to new positions. The diabetes specialist, which employs more than 42,000 people in 79 countries, has seen growth slow due to pricing pressures in the United States, where it makes about half its revenue. Novo Nordisk will next year have to pay higher rebates on U.S. healthcare scheme Medicare, the spokesman said.

  • Novo Nordisk to cut 250 jobs in the United States
    Reuters18 days ago

    Novo Nordisk to cut 250 jobs in the United States

    Denmark's Novo Nordisk will cut around 250 jobs in the United States, a spokesman told Reuters on Friday, adding the drugmaker would also hire an as-yet undetermined number of staff to new positions. The diabetes specialist, which employs more than 42,000 people in 79 countries, has seen growth slow due to pricing pressures in the United States, where it makes about half its revenue. Novo Nordisk will next year have to pay higher rebates on U.S. healthcare scheme Medicare, the spokesman said.

  • Investing in Diabetes Stocks: A Beginner's Guide
    Motley Fool19 days ago

    Investing in Diabetes Stocks: A Beginner's Guide

    Want to put money to work in this $825 billion market? Here's what you need to know.

  • Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®
    CNW Group19 days ago

    Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®

    Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®

  • Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus
    CNW Group25 days ago

    Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus

    Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus

  • Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
    Zacks27 days ago

    Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

    Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

  • Novo Nordisk lays off 400 staff in research & development unit
    Reuters28 days ago

    Novo Nordisk lays off 400 staff in research & development unit

    Novo Nordisk, the world's top maker of diabetes drugs, said on Tuesday that it will lay off 400 staff in Denmark and China as part of a broader restructuring of its research and development organisation. Novo Nordisk said in May that new U.S. legislation aimed at reining in high drug prices would cut its 2019 sales by 1-2 percent. It announced 1,000 job cuts in 2016 as competition among insulin producers increased and prices were squeezed by pharmacy benefit managers (PBMs) who administer drug programs for employers and health plans.